Search
St. John's Wort
go.drugbank.com/drugs/DB01323ApprovedInvestigationalNutraceuticalCategories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeLomerizine
go.drugbank.com/drugs/DB14065Experimental[A245383] This drug is used to prophylactically treat migraines[A245368, A245373] and is also being investigated against eye-related diseases that are associated with local circulatory disturbances, an
Tesaglitazar
go.drugbank.com/drugs/DB06536InvestigationalTesaglitazar is a dual peroxisome proliferator-activated receptor alpha/gamma agonist which improves apolipoprotein levels in non-diabetic subjects with insulin resistance.
Sacrosidase
go.drugbank.com/drugs/DB06760ApprovedSacrosidase is a liquid enzyme preparation from S.cerevisiae used for the treatment of congenital sucrose-isomaltase deficiency (CSID). People with CSID have variable amounts of sucrose-isomaltase enzyme activity and therefore have issue...
QazCovid-in
go.drugbank.com/drugs/DB16441InvestigationalIt demonstrated high efficacy, safety, and immunogenicity at 96% in initial Phase I and II trials (NCT04530357), and will now be undergoing upcoming Phase III trials[L30633, L30638].
Romifidine
go.drugbank.com/drugs/DB11543ExperimentalVet approvedThis drug's chemical structure closely resembles that of clonidine, however, romifidine is not approved for use in humans.
WNY0824
go.drugbank.com/drugs/DB23606Experimental[A274253] It is a dual inhibitor of PLK-1 and BRET-4, which have both been found to be involved in CRPC via suppression of AR/MYC-mediated transcription. [A274258]
Sampatrilat
go.drugbank.com/drugs/DB21283ExperimentalSampatrilat is a small molecule drug. Sampatrilat has a monoisotopic molecular weight of 584.25 Da.
Categories: Agents Acting on the Renin-Angiotensin SystemPF-06273340
go.drugbank.com/drugs/DB12269InvestigationalPf 06273340 is under investigation in clinical trial NCT01934738 (A Study to Evaluate Safety, Toleration and Time Course of Plasma Concentration of Multiple Oral Doses of PF-06273340 in Healthy Subjects
Human ciliary neurotrophic factor, recombinant (E. coli)
go.drugbank.com/drugs/DB17959ExperimentalThe trials were NCT03071965, an extension study of the NT-501 CNTF implant for macular telangiectasia, and NCT01949324, a Phase 2 multicenter randomized clinical trial of CNTF for macular telangiectasia